Generate:Biomedicines
@generate_biomed
Followers
5K
Following
58
Statuses
401
As pioneers in generative biology, we're revolutionizing the way biotherapeutics are discovered and developed.
Somerville, MA
Joined July 2020
Women hold just 22% of AI roles globally, according to @WEF’s Global Gender Gap Report 2024. Yet diverse perspectives are critical to driving innovation—especially in AI-powered drug discovery. At @generate_biomed, AI isn’t just a tool—it’s how we program biology to create new medicines. For International Day Of Women And Girls In Science, we’re highlighting Erin Yang, Hoda Aki, and Tharindi Hapuarachchi, who are applying machine learning to protein design, computational modeling, and platform strategy—advancing what’s possible in drug discovery. Read about their paths into AI, the role of mentorship, and the impact of bringing diverse expertise together: #February11
0
0
6
@Piper_Sandler "Virtual TSLP Day" on Friday, February 7 will take a deep dive into the evolving clinical development and treatment landscape for TSLP-targeting therapies in respiratory disease. Our CEO, @mike_nally , and EVP, R&D, Alexandra Snyder, MD, will take part in a fireside chat to discuss innovation, differentiation, and the future of this space. The event will also feature discussions with industry leaders from @Amgen , @AclarisTx, Apogee Therapeutics, and @UpstreamBio.
0
0
0
Last week, Generators gathered for a fireside chat with @FionaHMarshall, President of Biomedical Research at @NovartisScience, and our EVP, R&D, Alex Snyder. Fiona shared her perspective on how generative biology and AI are shaping the future of drug discovery. “Generative biology has the potential to go beyond traditional methods, allowing us to tackle challenges differently and explore new opportunities in science,” Fiona explained. Her visit highlighted the shared vision behind Novartis and Generate’s collaboration, announced last year, to leverage AI-driven technology for next-generation protein therapeutics. The discussion embodied our shared unapologetically scientific mindset and the need to embrace bold solutions to address unmet medical needs. Learn more about the collaboration:
0
0
2
What if biology and AI could unlock solutions to challenges once thought impossible? On #SolveForX, host @manjaselva speaks with @GVMaltzahn, one of our co-founders and a @FlagshipPioneer partner. Geoff shares how generative biology is creating new opportunities in medicine by combining cutting-edge AI with biology to target diseases in ways never before imagined. “At Generate, we’re seeing translational impact—therapies that couldn’t be designed through traditional means,” says Geoff. 🎧 Don’t miss this bold conversation about the future of medicine:
0
0
5
RT @FlagshipPioneer: Flagship, Cambridge University Health Partners (@CUHPartners), and Milner Therapeutics Institute (@TheMilnerInst) anno…
0
2
0
Generative AI is no longer theoretical—it’s delivering real impact in biology. In a CEO Chat moderated by @ChristineHeenan of @FlagshipPioneer, @mike_nally shares how we are programming biology to solve challenges once thought impossible. “Where generative AI uniquely unlocks biology is where we are focusing—solving diseases and challenges that were only dreams a few years ago.” Mike highlights how tools like CryoEM, breakthroughs in data-driven experimentation, and the expertise of our team are helping us accelerate discovery and unlock new possibilities in biology. Watch the full conversation below. 👇
From the #FlagshipStudio: @generate_biomed CEO @mike_nally explains how Generate is a case example of the power of polyintelligence as it brings together human, machine, and nature’s intelligence to pioneer generative AI technologies in biology. Catch the full CEO Chat for more on Generate’s expanding pipeline of programs and partnerships, including with @Amgen, @Novartis, and others: #JPM25
0
1
4
In Part 2 of @PharmaScrip series, “What Does 2025 Hold for Biopharma?” - executives, investors, and industry experts share insights on funding and deal-making trends for the year ahead. Our CFO, Jason Silvers, shares: “The most transformative change lies in the integration of generative AI and data-driven platforms into drug discovery. Companies adopting these technologies are setting new benchmarks for innovation, enabling dynamic partnerships that target scalable programs rather than single assets.”
0
0
0
RT @BiotechTVHQ: 𝐇𝐨𝐭 𝐓𝐨𝐩𝐢𝐜𝐬: Yesterday, we asked @FlagshipPioneer's @NoubarAfeyan about one of the hottest topics of discussion in the indu…
0
3
0
In the @FlagshipPioneer annual letter, Founder & CEO @NoubarAfeyan reflects on polyintelligence — the synthesis of human, machine, and nature’s intelligence — and its transformative potential in science and medicine. Noubar writes: “At @generate_biomed, we’re systematically combining nature’s intelligence and artificial intelligence to design entirely new proteins that address unmet medical needs with precision and intentionality.” This vision is coming to life across Flagship Founded companies like Generate, where polyintelligence is unlocking new possibilities in human health.
Read or listen to Flagship Pioneering’s 2025 Annual Letter in which Founder & CEO @NoubarAfeyan explores polyintelligence — the synthesis of human, machine, and nature's intelligence, and how it is driving a new renaissance in science and technology: Drawing inspiration from Leonardo da Vinci's integrated thinking, Noubar discusses how artificial intelligence will enhance our understanding of nature's adaptive genius in unprecedented ways. He highlights breakthroughs in biotechnology, agriculture, and machine intelligence, and how these polyintelligent innovations can tackle multifaceted challenges in health, climate, and beyond. And for more on how polyintelligence is informing and guiding Flagship’s work, dive into our newly launched Special Section: #BiggerLeaps #FlagshipStudio #JPM25
0
0
5
On Monday, January 13, at 3:00pm PT, @mike_nally our CEO, will join a panel hosted by @thermofisher at #JPM2025 to discuss “The Future of Drug Discovery and Clinical Development: How Can We Accelerate Value from Digital and AI?” Mike will join an incredible lineup of speakers: Najat Khan of @RecursionPharma , Gianluca Pettiti of @thermofisher, Vijay Pande, PhD of @a16z, and Aviv Regev of @genentech. Together, they’ll explore how digital and AI innovations are reshaping healthcare—from separating hype from reality to championing ethical and responsible use. Don't miss out – email TFS today to request an invite: DataAIPanel2025@thermofisher.com
0
0
3
On Monday, January 13, at 7:30am PST, @mike_nally our CEO will take the stage at #JPM2025 to provide an update on our AI platform and our advancing pipeline. With nearly 20 programs underway, we are combining generative AI with experimental innovation to tackle undruggable and hard-to-drug targets and optimizing molecules with unprecedented precision. Together, we're creating differentiated medicines and transforming the very process by which they are made. See how we're establishing programmable biology as a catalyst for new possibilities in medicine:
0
0
3
As we kick off 2025, here’s a question: What will you do to shape the future of human health? Our Machine Learning Summer Internship offers a unique opportunity to advance research in protein sequence, structure, and function — applying discoveries to therapeutic generation. During this three-month program, you’ll work with a mentor and collaborate with our unapologetically scientific team to develop high-quality code, tackle complex challenges, and drive impactful discoveries. At @generate_biomed, we believe relentless curiosity and collaboration fuel progress, empowering diverse teams to turn bold ideas into transformative solutions. Ready to join us? Apply now:
0
0
14
RT @lmgbio: .@mike_nally @generate_biomed discusses the innovative use of generative AI in drug discovery and the potential of generative A…
0
1
0
Meet Nvidia CEO Jensen Huang, the man behind the company powering today's artificial intelligence via @60minutes
0
0
1
Missed it the first time? This Sunday, @60Minutes will re-air its segment on @nvidia's groundbreaking role in AI. The episode explores how their innovations in computing power are transforming industries—including drug discovery. Alexandra Snyder, MD, our EVP of R&D, shares how generative AI is enabling us to unlock new possibilities in biology and create purpose-built protein therapeutics designed to address complex challenges in human health. Tune in Sunday at 7:00pm ET on @CBS to see how technology and biology are creating bold solutions for patients.
0
4
11
As biopharma VC investments focus on phase 2 data in 2025, platforms applying generative AI to biologics, like ours, continue to stand out. See why @FierceBiotech and @James_Waldron note AI’s staying power:
0
0
2
As we wrap up 2024, we reflect on this extraordinary moment in history where innovation is accelerating at an unprecedented pace. Generative Biology is part of this moment, offering bold new ways to tackle some of the toughest challenges in human health. At @generate_biomed, we’re proud to be part of this revolution, advancing ideas that challenge the status quo and solutions designed to make a difference. The spirit of innovation and connection is always with us, and our annual ugly sweater event was a fun example of that—celebrating our fiercely united culture and the creativity and collaboration that fuel everything we do. Moments like these remind us that the breakthroughs of tomorrow are powered by the relationships and shared purpose we build today. As we look to 2025, we’re inspired by what’s ahead: unplanned discoveries, bold new ideas, and the opportunity to turn vision into impact.
0
0
1
Debate on Solving Immuno-Oncology's Top Challenges
0
0
2
This Week in Health News: 12 Stories You Need to See
0
0
2
A primer on machine learning in cryo-electron microscopy (cryo-EM) - LessWrong via @trendkite
0
0
12